Clinical Data Presented At Asia Pcr/sing Live Demonstrate Benefits Of Orbusneich's Genoust Bio-engi

< BACK TO BIOTECHNOLOGY starstarstarstarstar   Science - Biotechnology Press Release
2nd February 2010, 07:00pm - Views: 636

People Feature OrbusNeich 2 image


Clinical Data Presented at Asia PCR/Sing LIVE  Demonstrate Benefits of OrbusNeich's GenousT Bio-

engineered R stentT in Challenging Patient Subsets

HONG KONG, Feb. 2/Media OutReach-AsiaNet/--

Presentations Focus on Patients with Bifurcation Lesions and Non-ST-Segment   

               Elevation Acute Coronary Syndrome

    OrbusNeich announced that clinical data presented at Asia PCR/Singapore LIVE 2010 demonstrated the

benefits of the Genous Bio-engineered R stent in the treatment of two challenging patient subsets.

   Specifically, presentations delivered by Prof. Robbert de Winter, M.D., Ph.D., of the Academic Medical

Center (AMC) in Amsterdam and Wojciech Wojakowski, M.D., from Medical University of Silesia in Poland

focused on the use of the Genous Bio-engineered R stent in patients with bifurcation lesions and patients with

non ST-segment elevation acute coronary syndrome.

   Prof. de Winter's presentation, titled "One Year Clinical Outcome after Provisional T Stenting with the

Endothelial Progenitor Cell Capturing Stent for Bifurcation Lesions," featured a single-center study with 178

patients that compared the Genous Bio-engineered R stent to a previous bare metal stent control group of 465

patients at the AMC.  A 32 percent reduction of the composite of cardiac death, myocardial infarction or target

lesion revascularization was reported between these two groups. The cumulative rate of definite or probable

stent thrombosis was reduced by 57 percent in the Genous Bio-engineered R stent-treated group compared to

the control group.

   "Bifurcation lesions remain a challenge for interventional cardiologists," said Prof. de Winter. "The Genous

Bio-engineered R stent, with a low rate of stent thrombosis, is an alternative for this challenging patient group."

   Dr. Wojakowski presented data on the JACK-EPC trial, a comparison of the efficiency of high dose

atorvastatin and endothelial progenitor-capture stents versus bare metal stents, in the reduction of neointimal

formation in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS). The randomized

study with 60 patients compared the Genous Bio-engineered R stent with bare metal stents with concomitant

high dose atorvastatin in the reduction of neointimal hyperplasia assessed by coronary angiography and IVUS

after six months.

   In the JACK-EPC trial, the Genous Bio-engineered R stent induced less neointimal hyperplasia and a lower

binary restenosis rate of 13 percent in the Genous Bio- engineered R stent, compared to 26.6 percent in the

control group. Importantly, the major adverse cardiac events (MACE) rate was reported at only 10 percent in

the Genous Bio-engineered R stent treated patient group versus 16 percent in the bare metal stent treated


   "In our small study, we observed a lower amount of neo-intimal proliferation with the EPC capture stent

compared to the bare metal stent control," said Wojakowski. "Good safety is indicated by comparable stent

thrombosis.  We think this makes the Genous stent a very promising treatment strategy for ACS patients,

especially those with high risk of bleeding or not eligible for prolonged dual antiplatelet therapy due to allergy

to ASA or clopidogrel."

   "Data from both presentations support the use of the Genous Bio-engineered R stent as an effective

treatment option in what interventional cardiologists find to be challenging cases," said Al Novak,

OrbusNeich's chairman and CEO. "We look forward to continuing to work with physicians to realize the full

potential of the Genous technology. 


   Hong Kong Media Contacts: 

People Feature OrbusNeich 3 image

   Iva Ng


   Tel: (+852) 2802 2288

   Ruder Finn Asia

   Yvonne Au

   Ruder Finn Asia

   Tel: (+852) 2201 6448 

   SOURCE: OrbusNeich


To view this and other AsiaNet releases please visit

news articles logo NEWS ARTICLES
Contact News Articles |Remove this article